Medicenna is a clinical stage, privately held, immuno-oncology company developing novel first-in-class, Interleukin-4 Empowered Cytokinesé (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R).
Medicenna Therapeutics, Inc.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”MDNA.TO” api=”yf” style=”font-size: 15px”]
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/medicenna-therapeutics-corp.” connections=”true” suffix=””]
Its proprietary Empowered Cytokinesé are fusion proteins that combine the tumor selective targeting capabilities of engineered cytokines (Superkinesé) with potent pro-apoptotic (cell killing) payloads. Superkineé is a cytokine that has been engineered to bind with high affinity to a tumor specific cytokine receptor or receptor sub-type present on the surface of the target cell.
In Feb 2015, it has been awarded a product development grant of US$14.1 Mn from the Cancer Prevention and Research Institute of Texas (CPRI) to develop novel targeted therapeutics for cancer.